Xilio Therapeutics, INC 10-Q quarterly reports

Xilio Therapeutics files its Q2 2026 Form 10-Q, detailing increased collaboration revenue and ongoing R&D investments, while managing cash runway.

Xilio Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing increased collaboration revenue, higher R&D spending, and a strengthened cash position.

Xilio Therapeutics announced its Q3 2025 financial results, showing increased revenue from collaborations and extending its cash runway into Q1 2027, despite ongoing operating losses and a going concern doubt.

Xilio Therapeutics reported increased collaboration revenue and a significant capital raise, extending its cash runway through Q3 2026, despite ongoing operating losses and substantial doubt about its ability to continue as a going concern.

Xilio Therapeutics reports Q1 2025 results, highlighting a new collaboration with AbbVie while acknowledging substantial doubt about its ability to continue as a going concern.

Xilio Therapeutics' Q3 2024 report reveals ongoing losses and substantial doubt about its ability to continue as a going concern, despite a recent licensing deal with Gilead.

Xilio Therapeutics' Q2 2024 results show a net loss of $13.9 million and a license revenue of $2.4 million, while also expressing substantial doubt about its ability to continue as a going concern.

Xilio Therapeutics has entered into an exclusive license agreement with Gilead, receiving $43.5 million upfront and potentially over $600 million in milestones, while also reprioritizing its clinical pipeline.